| 1364 |
National Cancer Institute |
Html |
en |
Sleep Disorders (PDQ®)–Health Professional Version |
Expert-reviewed information summary about causes and management of sleep disorders in people with cancer. |
| slow wave sleep | 0.645037 |
| sleep difficulty | 0.586858 |
| circadian sleep disorder | 0.585999 |
| sleep disturbance | 0.734742 |
| general sleep | 0.627531 |
| self-reported sleep | 0.586211 |
| sleep disturbances | 0.78937 |
| sleep environment | 0.599417 |
| general sleep hygiene | 0.610843 |
| sleep history | 0.590036 |
| poor sleep hygiene | 0.618457 |
| sleep patterns | 0.707388 |
| individual sleep patterns | 0.650508 |
| sleep cycle. | 0.613137 |
| sleep diary | 0.632064 |
| subjective sleep quality | 0.612249 |
| sleep disruption | 0.616368 |
| severe sleep | 0.619271 |
| sleep medicine report | 0.579291 |
| Pittsburgh Sleep Quality | 0.612644 |
| 8-hour sleep period. | 0.649042 |
| General Sleep Disturbance | 0.626985 |
| different sleep trajectories | 0.61732 |
| secondary sleep disorders | 0.654958 |
|
| behavioral therapy | 0.643973 |
| cancer experience sleep | 0.697426 |
| numerous sleep parameters | 0.602184 |
| sleep education | 0.598942 |
| REM sleep | 0.663854 |
| sleep | 0.906331 |
| diary-measured sleep variables | 0.59623 |
| sleep cycle | 0.621195 |
| sleep outcomes | 0.569139 |
| sleep medicine | 0.672639 |
| common sleep disturbance | 0.63638 |
| total sleep time | 0.611253 |
| sleep quality | 0.73817 |
| sleep disorders | 0.662401 |
| progressively deepening sleep | 0.64769 |
| Adequate sleep | 0.615183 |
| sleep restriction | 0.71475 |
| severe sleep disturbances | 0.604554 |
| breast cancer | 0.670406 |
| insomnia | 0.65868 |
| randomized controlled trial | 0.60112 |
| severe sleep disorder | 0.613455 |
| sleep hygiene | 0.685071 |
| NREM sleep | 0.616861 |
|
CLICK HERE |
| 1651 |
National Cancer Institute |
Html |
en |
Milk Thistle (PDQ®)–Patient Version |
Expert-reviewed information summary about the use of milk thistle as a treatment for people with cancer. |
| cancer treatment | 0.701214 |
| advanced liver cancer | 0.66555 |
| PDQ cancer information | 0.729457 |
| Cancer Complementary | 0.666923 |
| clinical trials | 0.798052 |
| U.S. Food | 0.649163 |
| cancer information summary | 0.699946 |
| alternative cancer therapies | 0.663524 |
| clinical trial | 0.731299 |
| CAM cancer research | 0.657056 |
| patients | 0.673877 |
| cancer patients | 0.654835 |
| randomized clinical trial | 0.683387 |
| Marian thistle | 0.690666 |
| NCI PDQ cancer | 0.677418 |
| cancer information database | 0.662437 |
| radiation therapy | 0.660512 |
| Therapies Editorial Board | 0.664492 |
| cancer information | 0.734643 |
| treatment | 0.70795 |
| cancer prevention | 0.650452 |
| Complementary Therapies Editorial | 0.677699 |
| United States | 0.665688 |
| Drug Administration | 0.682045 |
|
| Cancer Information Specialist | 0.658528 |
| cancer cells | 0.669779 |
| milk thistle supplements | 0.741182 |
| cancer cell lines | 0.655527 |
| anticancer medications | 0.651405 |
| Cancer Information Service | 0.697895 |
| CAM therapies | 0.649867 |
| treatment clinical trials | 0.654645 |
| National Cancer Institute | 0.770559 |
| alternative medicine | 0.692591 |
| conventional treatment | 0.650077 |
| St. Mary thistle | 0.707197 |
| Federal Trade Commission | 0.651646 |
| silymarin | 0.670265 |
| Cancer Care page | 0.650369 |
| breast cancer | 0.668147 |
| PDQ summary | 0.650118 |
| cancer clinical trials | 0.667946 |
| alternative therapies | 0.674881 |
| acute lymphoblastic leukemia | 0.665296 |
| neck cancer | 0.65549 |
| cancer information summaries | 0.662842 |
| colorectal cancer cells | 0.652543 |
| cancer | 0.828322 |
|
CLICK HERE |
| 1907 |
National Cancer Institute |
Html |
es |
Tratamiento de la leucemia linfoblástica aguda en adultos (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento de la leucemia linfoblástica aguda en adultos. |
| siguientes procedimientos | 0.512309 |
| células madre | 0.745172 |
| posibles factores | 0.503357 |
| leucemia linfocÃtica aguda | 0.520357 |
| sudores nocturnos | 0.503905 |
| leucemia linfoblástica aguda | 0.974441 |
| células madre formadoras | 0.514124 |
| hueso compacto | 0.512997 |
| neoplasias mieloides | 0.503724 |
| vÃa oral | 0.502952 |
| rayos x | 0.503057 |
| tirosina cinasa mesilato | 0.506883 |
| enlace drugs approved | 0.528959 |
| largo plazo | 0.502247 |
| cromosoma filadelfia | 0.520834 |
| célula madre mieloide | 0.525688 |
| células t | 0.514618 |
| efectos tardÃos | 0.513015 |
| células anormales.ampliar aspiración | 0.521673 |
| lÃquido cefalorraquÃdeo | 0.529356 |
| punción espinal.Ampliar | 0.503734 |
|
| National Cancer Institute | 0.502969 |
| siguientes riesgos | 0.502423 |
| Instituto Nacional | 0.509996 |
| célula madre linfoide | 0.511194 |
| PDQ Tratamiento | 0.507876 |
| general empeora | 0.503285 |
| presente sección | 0.502319 |
| leucemia mielógena | 0.512372 |
| sistema nervioso central | 0.612 |
| Physician Data Query | 0.510454 |
| linfocitos t | 0.513897 |
| leucemia mieloide aguda | 0.535285 |
| siguientes enlaces | 0.502726 |
| célula madre | 0.560418 |
| células sanguÃneas maduras | 0.551656 |
| células formadoras | 0.516721 |
| Filadelfia".Ampliar Cromosoma Filadelfia | 0.507706 |
| terapia posremisión | 0.505736 |
| cuidado paliativo | 0.502192 |
| siguientes pruebas | 0.518516 |
|
CLICK HERE |
| 1987 |
National Cancer Institute |
Html |
es |
Tratamiento de los tumores embrionarios del sistema nervioso central infantil (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del meduloblastoma infantil, los tumores embrionarios distintos del meduloblastoma y los tumores pineales infantiles. |
| sumario versa | 0.501558 |
| siguientes procedimientos | 0.502311 |
| células madre | 0.524991 |
| efectos secundarios meses | 0.503043 |
| siguientes aspectos | 0.500523 |
| años edad | 0.500492 |
| tratamiento mejora | 0.501438 |
| dosis pequeñas administras | 0.501281 |
| PDQ Descripción | 0.501938 |
| sección información | 0.50094 |
| efectos tardÃos | 0.505196 |
| carcinoma nevoide | 0.50085 |
| PDQ Tumores | 0.506016 |
| PDQ Efectos tardÃos | 0.501814 |
| lÃquido cefalorraquÃdeo | 0.521206 |
| punción espinal.Ampliar | 0.500903 |
| National Cancer Institute | 0.5005 |
| tumores benignos | 0.508351 |
| siguientes riesgos | 0.500413 |
| médula ósea.ampliar aspiración | 0.502403 |
| Instituto Nacional | 0.501732 |
|
| PDQ Tratamiento | 0.505028 |
| presente sumario | 0.501062 |
| determinados cambios | 0.501002 |
| riesgo promedio | 0.513411 |
| nuevos tipos | 0.500625 |
| riesgo alto.Riesgo promedio | 0.501723 |
| sistema nervioso central | 0.814928 |
| Physician Data Query | 0.50178 |
| brain tumor | 0.501055 |
| prueba irm | 0.500762 |
| Aboutâ„¢ Brain Tumors | 0.500627 |
| siguientes enfermedades | 0.501038 |
| cuánto tumor | 0.503396 |
| tumores embrionarios | 0.994005 |
| imágenes seguirán | 0.500378 |
| Cuánto tiempo | 0.500383 |
| siguientes enlaces | 0.500476 |
| SNC infantil recidivantes | 0.502864 |
| Brain Tumor Consortium | 0.501941 |
| infantil recidivantes | 0.502523 |
| siguientes pruebas | 0.501153 |
|
CLICK HERE |
| 2009 |
National Cancer Institute |
Html |
es |
Trasplante de células hematopoyéticas en la niñez (PDQ®)–Versión para profesionales de salud |
Información revisada por expertos acerca del uso del trasplante de células madre hematopoyéticas para el tratamiento del cáncer infantil. |
| mujeres donantes | 0.306393 |
| múltiples incompatibilidades | 0.305809 |
| HLA A | 0.36555 |
| incompatibilidades ich-o | 0.306724 |
| células progenitoras | 0.322599 |
| Sin embargo | 0.310448 |
| mejores abordajes | 0.305856 |
| cordón umbilical mo | 0.310246 |
| bone marrow relapse | 0.305504 |
| células t | 0.3408 |
| Marrow Transplant | 0.341721 |
| Moderado Bajo | 0.314512 |
| donantes momentos | 0.307307 |
| stem cell transplantation | 0.321131 |
| clase ii | 0.317893 |
| donante fraterno | 0.317133 |
| madre hematopoyéticas cmsp | 0.31029 |
| Children's Oncology Group | 0.30909 |
| intensive chemotherapy | 0.305653 |
| TCH satisfactorios | 0.311984 |
| siguientes antÃgenos | 0.307763 |
| donantes mujeres | 0.306338 |
| Transplant Clinical Trials | 0.309697 |
| HLA DRB1 | 0.341366 |
| eich aguda | 0.310608 |
|
| DRB1 HLA DQB1 | 0.319182 |
| dirección r-o | 0.30821 |
| HLA DPB1 | 0.318384 |
| células madre | 0.997289 |
| donantes varones | 0.306485 |
| células cd34+ | 0.310327 |
| leucemia linfoblástica aguda | 0.30978 |
| marrow transplantation versus | 0.305832 |
| bone marrow transplantation | 0.335932 |
| Clinical Trials Network | 0.307815 |
| stem cell | 0.328901 |
| Oncology Group study | 0.308699 |
| células cd34 | 0.331629 |
| antÃgeno hla | 0.332107 |
| Blood Marrow Transplant | 0.306328 |
| células madre hla | 0.331292 |
| eich aguda moderado | 0.306115 |
| PDQ Tratamiento | 0.308981 |
| bone marrow | 0.352242 |
| células progenitoras cd34 | 0.312061 |
| Marrow Transplant Research | 0.305769 |
| células madre resultante | 0.314653 |
| incompatibilidades r-o | 0.306646 |
| EICH crónica | 0.314484 |
|
CLICK HERE |
| 4388 |
National Cancer Institute |
Html |
en |
Risk Factors for Cancer |
Information about behaviors, exposures, and other factors that may influence the risk of cancer. |
| possible inherited cancer | 0.579042 |
| sign | 0.325482 |
| section | 0.325244 |
| protective factors | 0.646351 |
| avoidable risk factors | 0.633812 |
| media | 0.323442 |
| type | 0.323483 |
| certain behaviors | 0.496195 |
| wrong ideas | 0.432065 |
| research | 0.328222 |
| result | 0.323043 |
| true risk factor | 0.577461 |
| things | 0.325771 |
| Common Cancer Myths | 0.549129 |
| Hereditary Cancer Syndromes | 0.581459 |
| Misconceptions page | 0.432753 |
| relationship | 0.322662 |
| increased risk | 0.439428 |
| chemicals | 0.326011 |
| potential risk factor | 0.567711 |
| risk factors | 0.923045 |
| certain substances | 0.487633 |
|
| genetic mutations | 0.443709 |
| chance | 0.323016 |
| protective risk factors | 0.672248 |
| certain cancers | 0.611938 |
| lower risk | 0.460281 |
| epidemiology studies | 0.437177 |
| large groups | 0.438561 |
| finding | 0.323802 |
| people | 0.373455 |
| certain risk factors | 0.746622 |
| exposure | 0.356743 |
| chances | 0.333077 |
| scientists | 0.343939 |
| family history | 0.579318 |
| certain ways | 0.482584 |
| person | 0.360237 |
| Cancer risk factors | 0.679541 |
| n’t | 0.355491 |
| cancer | 0.820183 |
| information | 0.349749 |
| similar association | 0.428532 |
| possible mechanism | 0.423041 |
|
CLICK HERE |
| 16643 |
National Cancer Institute |
Html |
es |
Régimen Gonzalez (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos sobre el uso del régimen Gonzalez como tratamiento para personas con cáncer. Nota: La información contenida en este sumario ya no se actualiza y se ofrece solo con fines de consulta. |
| Centro Nacional | 0.304069 |
| New Hampshire Avenue | 0.301293 |
| Drug Administration | 0.300803 |
| estadio ii | 0.30117 |
| NCI Best Case | 0.302468 |
| datos bibliográficos pubmed | 0.301383 |
| siguientes preguntas | 0.300833 |
| supervivencia promedio | 0.301242 |
| James Beard | 0.301166 |
| PDQ Régimen Gonzalez | 0.309993 |
| National Cancer Institute | 0.301582 |
| estudio clÃnico | 0.301423 |
| siguientes riesgos | 0.301039 |
| Instituto Nacional | 0.310951 |
| Salud Complementaria | 0.305346 |
| Visuals Online | 0.30094 |
| complementarias revisa | 0.301324 |
| siguientes efectos | 0.301323 |
|
| Physician Data Query | 0.305467 |
| enzimas pancreáticas | 0.367516 |
| Estados Unidos | 0.312379 |
| régimen gonzalez | 0.988904 |
| libre uso | 0.300947 |
| página manejo | 0.300877 |
| Medicina Alternativa | 0.30166 |
| ¿El tratamiento | 0.301547 |
| ¿Los beneficios | 0.30081 |
| juntos cam | 0.300775 |
| siguientes formas | 0.301287 |
| William Kelley | 0.301175 |
| Clinical Oncology | 0.301179 |
| Nicholas Gonzalez | 0.323344 |
| Max Gerson | 0.301216 |
| enzimas.Los resultados | 0.300995 |
| Series Program | 0.300797 |
| medicina complementaria | 0.336883 |
|
CLICK HERE |
| 16833 |
National Cancer Institute |
Html |
en |
News and Events |
The latest news from the Office of Cancer Nanotechnology Research and the Alliance, as well as upcoming and past events attended by the Office of Cancer Nanotechnology Research staff, and relevant upcoming scientific meetings. |
| National Cancer Institute | 0.924974 |
|
|
CLICK HERE |
| 16849 |
National Cancer Institute |
Html |
en |
Earlier Detection and Diagnosis |
Winning the battle in cancer is by way of its earlier detection. Find out here how nanotechnology for cancer can enable the next generation of diagnostics. |
| molecular contrast agents | 0.744126 |
| magnetic resonance | 0.73913 |
| gold nanoparticles | 0.758974 |
| contrast agents | 0.928653 |
| specific tumor type | 0.759045 |
| nanoparticles | 0.799664 |
| Kettering Cancer Center | 0.72147 |
| single cancer cell | 0.739114 |
| prostate cancer cells | 0.750158 |
| local tumor response | 0.753856 |
| self-assemblying nanoparticles | 0.709894 |
| image contrast agents | 0.719631 |
| current nanoscale imaging | 0.726633 |
| tumor specific tissue | 0.778585 |
| tumor types | 0.710578 |
| magnetic resonance imaging | 0.73549 |
| tissue biopsies | 0.710788 |
| single cell level | 0.706857 |
| tumor tissue | 0.754041 |
| cancer cells | 0.798935 |
| magnetic nanoparticles | 0.748727 |
| Current imaging methods | 0.720015 |
| surgical resection | 0.752605 |
| molecular imaging agents | 0.749026 |
| imaging contrast agents | 0.752812 |
|
| Bioactivatable nanoparticles | 0.713538 |
| tumor pre-seeding | 0.710938 |
| novel imaging modalities | 0.716395 |
| tumor growth | 0.708481 |
| clinical cancer imaging | 0.759447 |
| tumor cells | 0.829828 |
| optical imaging contrast | 0.737025 |
| lung cancer patients | 0.707897 |
| Stanford University | 0.729305 |
| modern imaging modalities | 0.717085 |
| biological signatures | 0.716262 |
| cancer detection | 0.708688 |
| clinical cancer treatment | 0.738765 |
| brain tumor | 0.708929 |
| single circulating tumor | 0.753922 |
| cancer cell death | 0.775613 |
| Raman spectroscopic imaging | 0.712792 |
| imaging modalities | 0.740521 |
| MRI-PAT-Raman nanoparticles | 0.710131 |
| silica-hybrid nanoparticles | 0.709652 |
| prostate cancer | 0.754477 |
| tumor DNA | 0.744446 |
| cancer patient treatment | 0.749464 |
| cell-free tumor DNA | 0.731784 |
|
CLICK HERE |
| 17276 |
National Cancer Institute |
Html |
es |
Su propio cuidado |
Cuidar a alguien con cáncer avanzado trae desafíos y preocupaciones nuevas. Es importante que también se cuide a usted mismo y que pida ayuda. |
| Lotsa Helping Hands | 0.77931 |
| busque ayuda | 0.925738 |
|
|
CLICK HERE |